Physician profile
Kellie E Clayton
NPI 1669898433
$15,489.79
in general payments reported to CMS, 2019-2025
56 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,955 · 2022: $4,267 · 2023: $3,180 · 2024: $3,712 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,130 · Long Term Medical Supply Or Device Loan: $598 · Consulting Fee: $440 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,130.45 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Consulting Fee | $440.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,543.96 | 2021-2025 | |
| Pfizer INC. | $1,265.30 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $913.58 | 2021-2024 | Keytruda, Lynparza, Reblozyl |
| Deciphera Pharmaceuticals INC. | $812.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $739.54 | 2021-2024 | Tagrisso, Calquence, Enhertu |
| Janssen Biotech, INC. | $693.37 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $659.09 | 2021-2024 | Opdivo, Opdualag, Krazati |
| Genzyme Corporation | $657.75 | 2021-2024 | |
| Incyte Corporation | $607.40 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $574.96 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Stemline Therapeutics INC. | $548.26 | 2024 | Orserdu |
| Epizyme, INC. | $485.45 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $485.38 | 2021-2024 | Libtayo |
| Gilead Sciences, INC. | $412.03 | 2022-2024 | Trodelvy |
| Celgene Corporation | $411.57 | 2021-2024 | Reblozyl, Pomalyst |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $387.20 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $366.17 | 2021-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $296.59 | 2023-2024 | Krazati |
| Lilly USA, LLC | $288.13 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $249.05 | 2021 | |
| Aveo Pharmaceuticals, INC. | $245.92 | 2021-2024 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $219.19 | 2021-2024 | |
| Morphosys, US INC. | $206.79 | 2021-2023 | Monjuvi |
| Glaxosmithkline, LLC. | $188.47 | 2021-2024 | Jemperli, Shingrix, Ojjaara |
| Astellas Pharma US INC | $180.76 | 2022-2024 | Xtandi, Xospata, Padcev |
| Abbvie INC. | $172.66 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.24 | 2021-2024 | Ninlaro, Iclusig |
| Genentech USA, INC. | $166.55 | 2021-2024 | Perjeta, Phesgo, Itovebi |
| Amgen INC. | $163.44 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Exelixis INC. | $154.97 | 2021-2024 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $145.98 | 2021-2024 | Precisetumor, Myrisk |
| Tersera Therapeutics LLC | $94.14 | 2021-2023 | Zoladex |
| Genmab U.S., INC. | $87.28 | 2024 | Epkinly |
| Emd Serono, INC. | $86.14 | 2023-2024 | Bavencio |
| Kite Pharma, INC. | $77.54 | 2022-2024 | Yescarta |
| Jazz Pharmaceuticals INC. | $75.66 | 2023-2024 | |
| Taiho Oncology, INC. | $66.91 | 2021-2024 | |
| Clovis Oncology, INC. | $63.87 | 2021-2022 | |
| Blueprint Medicines Corporation | $48.64 | 2023-2024 | Ayvakit |
| Myovant Sciences INC. | $46.89 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $44.72 | 2022 | |
| Sobi, INC | $42.91 | 2022-2023 | |
| Tg Therapeutics, INC. | $41.32 | 2021-2022 | |
| Array Biopharma INC | $37.21 | 2023-2024 | Braftovi, Lorbrena, Xalkori |
| Adc Therapeutics America, INC. | $36.37 | 2023 | |
| Beigene USA, INC. | $33.96 | 2022-2024 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.65 | 2021-2024 | Gilotrif |
| Alnylam Pharmaceuticals INC. | $26.18 | 2024 | Givlaari |
| Amag Pharmaceuticals, INC. | $24.10 | 2021 | |
| Pharmaessentia USA Corporation | $22.43 | 2023 | Besremi |
| Spectrum Pharmaceuticals INC. | $20.42 | 2023 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $15.49 | 2022 | |
| Novocure INC. | $14.73 | 2024 | Optune Lua (Novottf-200t) |
| Heron Therapeutics, INC. | $14.72 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.94 | 2024 | Sancuso |
| Acceleron Pharma, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Clayton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.